Detalle Publicación

ARTÍCULO
Evaluation of sustained minimal Rresidual disease negativity with Daratumumab-combination regimens in relapsed and/or refractory multiple myeloma: analysis of POLLUX and CASTOR
Autores: Avet-Loiseau, H. (Autor de correspondencia); San Miguel Izquierdo, Jesús; Casneuf, T.; Iida, S.; Lonial, S.; Usmani, S. Z.; Spencer, A.; Moreau, P.; Plesner, T.; Weisel, K.; Ukropec, J.; Chiu, C.; Trivedi, S.; Amin, H.; Krevvata, M.; Ramaswami, P.; Qin, X.; Qi, M.; Sun, S.; Qi, M.; Kobos, R.; Bahlis, N. J.
Título de la revista: JOURNAL OF CLINICAL ONCOLOGY
ISSN: 0732-183X
Volumen: 39
Número: 10
Páginas: 1139 - 1149
Fecha de publicación: 2021
Resumen:
PURPOSE In relapsed and/or refractory multiple myeloma, daratumumab reduced the risk of progression or death by > 60% in POLLUX (daratumumab/lenalidomide/dexamethasone [D-Rd]) and CASTOR (daratumumab/bortezomib/dexamethasone [D-Vd]). Minimal residual disease (MRD) is a sensitive measure of disease control. Sustained MRD negativity and outcomes were evaluated in these studies. METHODS MRD was assessed via next-generation sequencing (10(-5)) at suspected complete response (CR), 3 and 6 months following confirmed CR (POLLUX), 6 and 12 months following the first dose (CASTOR), and every 12 months post-CR in both studies. Sustained MRD negativity (>= 6 or >= 12 months) was evaluated in the intention-to-treat (ITT) and >= CR populations. RESULTS The median follow-up was 54.8 months in POLLUX and 50.2 months in CASTOR. In the ITT population, MRD-negativity rates were 32.5% versus 6.7% for D-Rd versus lenalidomide and dexamethasone (Rd) and 15.1% versus 1.6% for D-Vd versus bortezomib and dexamethasone (Vd; both P < .0001). Higher MRD negativity rates were achieved in >= CR patients in POLLUX (D-Rd, 57.4%; Rd, 29.2%; P = .0001) and CASTOR (D-Vd, 52.8%; Vd, 17.4%; P = .0035). More patients in the ITT population achieved sustained MRD negativity >= 6 months with D-Rd versus Rd (20.3% v 2.1%; P < .0001) and D-Vd versus Vd (10.4% v 1.2%; P < .0001), and >= 12 months with D-Rd versus Rd (16.1% v 1.4%; P < .0001) and D-Vd versus Vd (6.8% v 0%). Similar results for sustained MRD negativity